Page 67 - NobleCon20-Book-Project

Eledon Pharmaceuticals, Inc.

SELECTED FINANCIAL ITEMS ELDN

(in millions of USD)
CQ4 '23 CQ1 '24 CQ2 '24 CQ3 '24 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (10.34) (10.87) (14.50) (20.51) (56.22)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (85.84) (23.63) (44.91) 76.97 (77.40)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 89.07 80.82 120.48 114.58 114.58
Cash & Short Term Investments 4.61 5.66 26.04 6.75 6.75
% of Assets 5% 7% 22% 6% 6%
Current Assets -Total 56.13 47.98 87.22 81.51 81.51
% of Assets 63% 59% 72% 71% 71%
Total Liabilities 81.86 6.00 128.98 38.52 38.52
% of Assets 92% 7% 107% 34% 34%
Current Liabilities - Total 3.90 4.25 6.03 12.49 12.49
% of Assets 4% 5% 5% 11% 11%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 7.21 74.82 (8.50) 76.06 76.06
% of Assets 8% 93% -7% 66% 66%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (9.13) (8.74) (7.77) (11.77) (37.42)
Net Cash Flow - Investing 10.08 9.78 (19.91) (12.80) (12.86)
Net Cash Flow - Financing 0.00 0.00 48.07 5.28 53.36

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twentieth Annual Small & Microcap Investor Conference